engleski

Thyroid hormones (131I-T3/T4) in serum and urine of patients with differentiated thyroid cancer

Patients with differentiated thyroid cancer are regularly followed-up by a whole body scan with radio-iodine (131-I), ultrasonography of the neck, and determination of serum thyroglobulin concentrations. It has been shown, however, that identification of endogenously radiolabelled tri-iodothyronine and thyroxine (131-I-T3/T4), determined in serum by a chromatographic method, may serve as a useful additional test. The aim of this study was to determine whether urine, as well as sera of differentiated thyroid cancer patients, contains 131-I-T3/T4, and to compare results of chromatographic studies with those from other relevant tests. Thirteen patients, nine with papillary and four with follicular cancers, were included in this preliminary study. All patients had undergone thyroidectomy and radioablation of the thyroid remnant with a single dose of 100 mCi (3.7 GBq) of 131-I. All 13 patients also had negative titres of thyroglobulin antibodies, and serum thyrotrophin concentrations > 30 mU/L. To facilitate comparison of tests, results for whole body scan, ultrasonography, thyroglobulin measurement and serum or urine chromatography were all expressed simply as positive or negative. Serum and urine chromatography results were both negative in six of 13 patients (46%), both positive in one patient (8%), and positive or negative in combination in six patients (46%). Variabilities in peak radioactivity of iodo-protein, iodide, 131-I-T3/T4 and di-iodothyronine suggest that differentiated thyroid cancer patients had different iodine metabolisms. At least one or both chromatography results were in accord with whole body scan, ultrasonography and thyroglobulin results in 11 patients (85%), and not in accord in two patients (15%). As a basic test in the follow-up of patients with differentiated thyroid cancer, whole body scan showed lack of accord with thyroglobulin results in four patients (31%), with ultrasonography results in three patients (23%), and with chromatography results in two patients (15%). Results indicate that the chromatography method, performed in both serum and urine of differentiated thyroid cancer patients, may provide a complementary method for their follow-up.

Thyroid hormones (131I-T3/T4) in serum and urine of patients with differentiated thyroid cancer

nije evidentirano